Simmons D, DerSarkissian M, Shenolikar R, et al. - Researchers undertook this retrospective analysis to evaluate clinical results related to starting EGFR-TKI (tyrosine kinase inhibitor) compared with other therapies in stage IV EGFR mutation (EGFRm) non-small cell lung cancer (NSCLC). They used Flatiron Health Electronic Health Record data and analyzed adults with stage IV EGFRm NSCLC who started first-line (1L) EGFR-TKI, immunotherapy (IO) (+ chemotherapy), or chemotherapy alone from May of 2017 to December of 2018. This study involved 593 patients with a mean age of 67.5 years and 65.4% of whom were women. EGFR-TKI was employed as 1L treatment for 77.2% of patients (n = 458), IO in 13.3% (n = 79) and chemotherapy in 9.4% (n = 56). Patients on EGFR-TKI had longer median duration of therapy (DoT) and median time to next therapy (TTNT) compared to patients on IO and chemo. Patients on EGFR-TKI had significantly decreased risk of discontinuing therapy or death (DoT) and initiating second-line therapy or death (TTNT) vs patients on IO or chemotherapy, as seen in the adjusted analyses. Findings revealed that IO + chemotherapy as 1L was initiated in a substantial number of patients, and better clinical results were seen with EGFR-TKI vs IO + chemotherapy, indicating the significance of following NCCN recommendations for therapy in stage IV EGFRm NSCLC patients.